APTN · Adaptin Bio, Inc. · Debt
$6.27
At close · Aug 19
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has evaluated the Company's operating plan against its existing cash and determined that substantial doubt exists about the Company's ability to support its operations and fund its obligations for the next twelve months from the date of issuance of these condensed consolidated financial statements.”View the 10-Q filed Aug 13, 2026
Market Cap
$57.89M
Shares
9.23M
Volume · Aug 19
200
Avg daily vol (12 sessions)
256
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current portion of convertible debt | 2024-12-31 | USD 1,248,708 | 10-K filed 2026-04-01 |
| Current portion of other notes payable | 2024-12-31 | USD 275,000 | 10-K filed 2025-04-15 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.